Literature DB >> 27000961

Haematological cancer: PomCyDex - a lower-cost option in refractory myeloma?

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27000961     DOI： 10.1038/nrclinonc.2016.47

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

Authors:  Rachid C Baz; Thomas G Martin; Hui-Yi Lin; Xiuhua Zhao; Kenneth H Shain; Hearn J Cho; Jeffrey L Wolf; Anuj Mahindra; Ajai Chari; Daniel M Sullivan; Lisa A Nardelli; Kenneth Lau; Melissa Alsina; Sundar Jagannath
Journal:  Blood       Date:  2016-03-01       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.